LNTH Lantheus Holdings, Inc.

FDA approval for BRAVNETSA puts Lantheus Holdings (LNTH) in focus Lantheus Holdings (LNTH) drew fresh attention after the FDA granted final approval for BRAVNETSA, a radiopharmaceutical considered bioequivalent and therapeutically equivalent to LUTATHERA for adult GEP NET patients. The BRAVNETSA approval lands at a time when Lantheus Holdings has seen short term share price pressure, with the stock down over the past three months. Yet its year to date share price return of 48.27% and 1 year...

Lantheus Holdings has delivered a powerful 5 year share price run, and the recent pullback leaves investors asking whether the current US$99.74 level is still grounded in the cash the business can generate. With fresh product news in its core radiopharmaceutical line, the question now is how far those future cash flows can stretch to back up today's valuation. Over the past 5 years the stock has returned 285.5%, which puts real pressure on the cash flow outlook to carry that kind of value...

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]

Lantheus currently trades at $100.02 and has been a dream stock for shareholders. It’s returned 270% since September 2021, blowing past the S&P 500’s 74.5% gain. The company has also beaten the index over the past six months as its stock price is up 32.1% thanks to its solid quarterly results.

Telix Pharmaceuticals (TLX) agreed to acquire Germany-based ITM Isotope Technologies Munich in a dea

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

Committed debt financing supporting the previously announced acquisition of Lantheus Holdings by Curium includes a senior secured multicurrency revolving credit facility and a $4.25 billion senior secured term loan B facility, according to a regulatory filing. In addition, Curium Midco entered into a separate commitment letter for a $1.125 billion PIK facility. The TLB and revolver will be incurred as additional facilities under Curium BidCo’s existing credit agreement, with JPMorgan as administ

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare equipment and supplies industry, including Lantheus (NASDAQ:LNTH) and its peers.

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 2.7% year on year to $388.2 million. Its non-GAAP profit of $1.55 per share was 18.9% above analysts’ consensus estimates.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 16.6% over the past six months while the S&P 500 was up 7.1%.

Curium has entered into a definitive agreement to acquire Lantheus Holdings (NasdaqGM:LNTH) in a transaction that will combine their radiopharmaceutical businesses. The deal was unanimously approved by the Lantheus Board and is set to create a larger global player in diagnostic and therapeutic radiopharmaceuticals. The combined group is expected to integrate product portfolios and development pipelines across key imaging and oncology markets. Lantheus Holdings focuses on...

Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.

(Updates with latest market prices and developments.) US stocks climbed intraday as oil prices fe

All three major US stock indexes were up in late-morning trading Monday after President Donald Trump

Lantheus (LNTH) has agreed to be acquired and taken private by Curium in an up to $8 billion deal th

Curium said it would pay $102.50 a share in cash for Lantheus, a 2.9% premium to Friday’s closing price of $99.64 and 8.5% above Lantheus’s closing price of $94.47 on May 21, before Bloomberg reported that Curium was circling the company.

Bloomberg reported that Curium is discussing a deal that would pay roughly $102 per Lantheus share in cash upfront plus an additional $12.50 per share in contingent value rights.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

What a fantastic six months it’s been for Lantheus. Shares of the company have skyrocketed 60.5%, hitting $105.30. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.